GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation
3:42 PMSeptember 19, 2018Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis ATLANTA, GA, Sept. 19, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a research article describing a study funded by the Gates Foundation. In the article, “Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model”, published at Gates Open Research1, the authors discussed their review of product development pipelines for 35
Read more